A randomized clinical trial of acellular pertussis vaccines in healthy adults

Dose-response comparisons of 5 vaccines and implications for booster immunization

Wendy A. Keitel, Larry R. Muenz, Michael D. Decker, Janet A. Englund, ChrisAnna M. Mink, Dean A Blumberg, Kathryn M. Edwards

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter, randomized, double-blind trial. A total of 481 healthy adults were given a single intramuscular booster dose of ACV or placebo. Three different dose levels were tested for 4 ACVs: full strength (the dose level proposed for infant immunization), one-third strength, and one-tenth strength. For 1 multicomponent vaccine, only the pertussis toxoid dose level varied. Minor injection site reactions were common and similar in frequency among vaccinated groups. Late-onset injection site reactions were seen in all ACV groups. Dose-related increases in mean antibody titers against vaccine antigens were seen after immunization with all ACVs. Antibody responses against antigens not known to be present in the vaccines were detected after immunization with 4/5 ACVs. Antibody levels fell significantly during the year after immunization. These data support evaluation of ACVs for broader use among adolescents and adults.

Original languageEnglish (US)
Pages (from-to)397-403
Number of pages7
JournalJournal of Infectious Diseases
Volume180
Issue number2
DOIs
StatePublished - 1999

Fingerprint

Acellular Vaccines
Pertussis Vaccine
Secondary Immunization
Vaccines
Randomized Controlled Trials
Immunization
Antigens
Injections
Antibodies
Antibody Formation
Placebos
Safety

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

A randomized clinical trial of acellular pertussis vaccines in healthy adults : Dose-response comparisons of 5 vaccines and implications for booster immunization. / Keitel, Wendy A.; Muenz, Larry R.; Decker, Michael D.; Englund, Janet A.; Mink, ChrisAnna M.; Blumberg, Dean A; Edwards, Kathryn M.

In: Journal of Infectious Diseases, Vol. 180, No. 2, 1999, p. 397-403.

Research output: Contribution to journalArticle

Keitel, Wendy A. ; Muenz, Larry R. ; Decker, Michael D. ; Englund, Janet A. ; Mink, ChrisAnna M. ; Blumberg, Dean A ; Edwards, Kathryn M. / A randomized clinical trial of acellular pertussis vaccines in healthy adults : Dose-response comparisons of 5 vaccines and implications for booster immunization. In: Journal of Infectious Diseases. 1999 ; Vol. 180, No. 2. pp. 397-403.
@article{6c47b6a5bb794491a591eaa0b4f35ca2,
title = "A randomized clinical trial of acellular pertussis vaccines in healthy adults: Dose-response comparisons of 5 vaccines and implications for booster immunization",
abstract = "The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter, randomized, double-blind trial. A total of 481 healthy adults were given a single intramuscular booster dose of ACV or placebo. Three different dose levels were tested for 4 ACVs: full strength (the dose level proposed for infant immunization), one-third strength, and one-tenth strength. For 1 multicomponent vaccine, only the pertussis toxoid dose level varied. Minor injection site reactions were common and similar in frequency among vaccinated groups. Late-onset injection site reactions were seen in all ACV groups. Dose-related increases in mean antibody titers against vaccine antigens were seen after immunization with all ACVs. Antibody responses against antigens not known to be present in the vaccines were detected after immunization with 4/5 ACVs. Antibody levels fell significantly during the year after immunization. These data support evaluation of ACVs for broader use among adolescents and adults.",
author = "Keitel, {Wendy A.} and Muenz, {Larry R.} and Decker, {Michael D.} and Englund, {Janet A.} and Mink, {ChrisAnna M.} and Blumberg, {Dean A} and Edwards, {Kathryn M.}",
year = "1999",
doi = "10.1086/314869",
language = "English (US)",
volume = "180",
pages = "397--403",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A randomized clinical trial of acellular pertussis vaccines in healthy adults

T2 - Dose-response comparisons of 5 vaccines and implications for booster immunization

AU - Keitel, Wendy A.

AU - Muenz, Larry R.

AU - Decker, Michael D.

AU - Englund, Janet A.

AU - Mink, ChrisAnna M.

AU - Blumberg, Dean A

AU - Edwards, Kathryn M.

PY - 1999

Y1 - 1999

N2 - The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter, randomized, double-blind trial. A total of 481 healthy adults were given a single intramuscular booster dose of ACV or placebo. Three different dose levels were tested for 4 ACVs: full strength (the dose level proposed for infant immunization), one-third strength, and one-tenth strength. For 1 multicomponent vaccine, only the pertussis toxoid dose level varied. Minor injection site reactions were common and similar in frequency among vaccinated groups. Late-onset injection site reactions were seen in all ACV groups. Dose-related increases in mean antibody titers against vaccine antigens were seen after immunization with all ACVs. Antibody responses against antigens not known to be present in the vaccines were detected after immunization with 4/5 ACVs. Antibody levels fell significantly during the year after immunization. These data support evaluation of ACVs for broader use among adolescents and adults.

AB - The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter, randomized, double-blind trial. A total of 481 healthy adults were given a single intramuscular booster dose of ACV or placebo. Three different dose levels were tested for 4 ACVs: full strength (the dose level proposed for infant immunization), one-third strength, and one-tenth strength. For 1 multicomponent vaccine, only the pertussis toxoid dose level varied. Minor injection site reactions were common and similar in frequency among vaccinated groups. Late-onset injection site reactions were seen in all ACV groups. Dose-related increases in mean antibody titers against vaccine antigens were seen after immunization with all ACVs. Antibody responses against antigens not known to be present in the vaccines were detected after immunization with 4/5 ACVs. Antibody levels fell significantly during the year after immunization. These data support evaluation of ACVs for broader use among adolescents and adults.

UR - http://www.scopus.com/inward/record.url?scp=0033511777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033511777&partnerID=8YFLogxK

U2 - 10.1086/314869

DO - 10.1086/314869

M3 - Article

VL - 180

SP - 397

EP - 403

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -